Aspirin or acetylsalicylic acid has been utilised by physicians for hundreds of years as an analgesic, anti-inflammatory and antipyretic ([@CIT0001]). Derived from plant sources, such as the willow tree, it has the ability to induce apoptosis in cancer cells and stimulate angiogenesis ([@CIT0002]--[@CIT0004]). Earlier research has established that the therapeutic benefit of willow is related to the pro-drug, β-[d]{.smallcaps}-salicin, which is metabolised to salicylic acid (SA) in the gastrointestinal system and blood ([Fig. 1](#F0001){ref-type="fig"}) ([@CIT0001], [@CIT0005]). Pharmacologically, SA is capable of modulating inflammation via the inhibition of the transcription factor, NF-κB, and subsequently the expression of COX-2 ([@CIT0005]). However, aspirin inhibits both COX-1 and -2 irreversibly, thereby inactivating prostanoid cascades for the production of prostaglandins, thromboxanes and prostacyclins, the essential fatty acid signalling molecules ([@CIT0006], [@CIT0007]). Thus, the non-specific mode of action of aspirin suggests the necessity for the development of more specific COX-2 inhibitors. Indeed, our recent research has clearly shown that a number of salicylate-related compounds exhibit modulation of inflammation and are more effective than aspirin ([@CIT0005], [@CIT0008]). For example, 4-hydroxybenzoate zinc was found to specifically inhibit COX-2 *via* the inactivation of the transcription factor NF-κB. Certainly, these were also more effective at inhibiting different cancer cell lines *in vitro* and in primary CLL cells when compared to aspirin ([@CIT0005], [@CIT0008], [@CIT0009]). Despite a host of pharmacological benefits, aspirin is associated with potential side effects such as peptic ulcers, deafness and dizziness in toxicity, and it is relatively contraindicated in children ([@CIT0010]). Therefore, further research into the potential of such aspirin-related compounds is imperative to produce safer and more targeted therapy.
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